Post-earnings recap
Reported
Thu, Nov 1, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
38%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kiniksa Pharmaceuticals reported a loss per share of $0.51, but the stock rose by 5.72% following the earnings report. The increase in stock price suggests that investors may be optimistic about the company's future potential, despite the lack of revenue data and guidance. The management's focus on pipeline development may have contributed to this positive sentiment.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.51 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Management acknowledged the ongoing development of their product pipeline. They emphasized their commitment to future growth despite not providing specific guidance.
Management did not provide specific revenue figures for the quarter.
The company remains focused on advancing its pipeline.